Over the next ten years, more than 15 million men worldwide Despite the tremendous potential of\u00a0the proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, limited market\u00a0access will restrict their impact on\u00a0the cardiovascular (CV) disease prevention landscape\u00a0beyond statins.\u00a0Low-density lipoprotein (LDL)-cholesterol is one of the key risk factors for\u00a0developing CV diseases, which are the leading cause\u00a0of death globally. The compelling LDL-cholesterol\u00a0lowering efficacy of the PCSK9 inhibitors means\u00a0this novel class has the potential to revolutionize\u00a0the management of hypercholesterolemia and\u00a0dramatically reduce the risk of CV morbidity and\u00a0mortality. Until late 2014, only the statins had recent,\u00a0high-quality data showing that the reductions in\u00a0LDL-cholesterol are associated with a reduction in\u00a0CV event rates. Since then, the positive IMPROVE-IT\u00a0results have reinforced the LDL-cholesterol lowering\u00a0hypothesis, and hopes are high that the\u00a0substantially more-efficacious PCSK9 inhibitors will\u00a0induce even more clinically meaningful reductions\u00a0in CV events. However, despite the leading PCSK9\u00a0inhibitor candidates having excellent risk-benefit\u00a0profiles, the rapid development, high cost, injectable\u00a0administration, and concerns about the antibody\u00a0formulation will weigh negatively against these\u00a0agents in the minds of key stakeholders, particularly\u00a0until any CV benefits are confirmed.<\/p>\n","protected":false},"template":"","class_list":["post-391290","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391290\/revisions"}],"predecessor-version":[{"id":576929,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391290\/revisions\/576929"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}